Bioxytran, Inc.

AI-generated fair value estimate for this company.

Method: Liquidation/net asset value: total liabilities of $5.01M exceed cash of $0.46M, producing negative net tangible assets of approximately -$4.55M against 113.36M common shares outstanding; a nominal $0.01/share value is assigned to reflect residual option value on the company's pipeline despite negative book equity.

Reasoning: Bioxytran has explicit going-concern doubt in its most recent 10-Q, negative working capital, and a cash runway that management says ends around September 2026, so neither a DCF nor a positive net-asset value is defensible; a nominal near-zero value reflects that common equity is effectively wiped out absent an unlikely near-term financing or licensing event.